Recent DIPG Research News

Finding a cure through funding vital research

There are currently very few treatments showing any efficacy (scientifically documented and proven) and no cure available for DIPG 

Research initiatives and funding of this work enabling doctors to get a better understanding of how DIPG develops and progresses, is the only way to lead development of effective treatment options, and techniques to benefit ALL children affected by DIPG.

Here are some of the latest developments :

25% of children with DIPG have a mutation in the ACVR1 gene with no targeted therapy - AI selected everolimus alongside vandetanib in combination with enhanced BBB penetration already tested in a small clinical cohort.

Sydney researchers identify/advance potential revolutionary new drug treatment for fatal childhood cancer 

Electrical and synaptic integration of glioma into neuronal circuits 

Release from the ICR regarding the first EVER specifically designed and 'targeted' therapy to treat DIPG patients with mutations in the ACVR1 gene. 

ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis 

Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma 

Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma 

Results from the MSKCC: Convection-enhanced delivery for diffuse intrinsic pontineglioma: a single-centre, dose-escalation, phase 1 trial 

Potent antitumor efficacy of Anti-GD2 CAR-T cells in H3 K27M +diffuse midline gliomas 

Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma 

Study splits incurable childhood brain tumours into 10 new diseases 

Targeting a protein called neuroligin-3 

Influence of an intratumoral cyst on drug distribution by convection-enhanced delivery: case report 

Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management 

Restoring the tumor suppressor gene p16 slows tumor growth in vitro 

EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. 

Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas 

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors 

BMI-1 is a Potential Therapeutic Target in Diffuse Intrinsic Pontine Glioma 

A phase I study of convection enhanced delivery (CED) of 124I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma (DIPG). 

External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. 

Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma

 Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models